Affymetrix Provides Aventis Pharmaceuticals Early Access to High-Throughput GeneChip(R) Platform
03 March 2004 - 10:00PM
PR Newswire (US)
Affymetrix Provides Aventis Pharmaceuticals Early Access to
High-Throughput GeneChip(R) Platform SANTA CLARA, Calif., March 3
/PRNewswire-FirstCall/ -- Affymetrix, Inc., today announced that
Aventis Pharmaceuticals has entered into an agreement that provides
Aventis early access to the new GeneChip(R) HighThroughputArray
(HTA) that uses a standard 96-well microtiter plate footprint to
simultaneously process and analyze 96 GeneChip Human Genome U133A
Arrays. "The GeneChip HTA system industrializes the workflow of
processing microarray-based experiments, creating a new
price/performance point in the industry," said Steve Lombardi, Vice
President of Corporate Development at Affymetrix. "HTA will enable
pharmaceutical companies to implement and apply GeneChip technology
in high-throughput drug development applications through its
reliability and lowered cost per experiment." The GeneChip HTA
system has the capacity to process hundreds of biological samples
per day with minimal human supervision, reducing capital, labor,
reagent, and array expenses. The GeneChip HTA system adapts the
same industry- standard GeneChip brand technology and content that
Affymetrix uses in its cartridges to a standard 96-array format,
which runs on an automated system built with off-the-shelf robotic
components. The GeneChip HTA system automates the most labor
intensive steps in GeneChip processing, dramatically reducing the
cost per assay. The decrease in cost and increase in throughput
enables industrialized genomics-based research and makes the
GeneChip HTA system well suited for downstream development
applications like compound profiling, toxicology and clinical
trials. The components of the GeneChip HTA system include the HTA
96-array plate, a new scanner for analyzing the HTA plates, the
automated assay adapted from Affymetrix' standard gene expression
assay, specifications for the automation components, and a software
system for tracking samples and data. Further development on the
system will enable high-throughput studies employing other products
and applications, including genotyping, resequencing and chromatin
immunoprecipitation. About Affymetrix: Affymetrix is a pioneer in
creating breakthrough tools that are driving the genomic
revolution. By applying the principles of semiconductor technology
to the life sciences, Affymetrix develops and commercializes
systems that enable scientists to improve quality of life. The
Company's customers include pharmaceutical, biotechnology,
agrichemical, diagnostics and consumer products companies as well
as academic, government and other non- profit research institutes.
Affymetrix offers an expanding portfolio of integrated products and
services, including its integrated GeneChip platform, to address
growing markets focused on understanding the relationship between
genes and human health. Additional information on Affymetrix can be
found at http://www.affymetrix.com/. All statements in this press
release that are not historical are "forward- looking statements"
within the meaning of Section 21E of the Securities Exchange Act as
amended, including statements regarding Affymetrix' "expectations,"
"beliefs," "hopes," "intentions," "strategies" or the like. Such
statements are subject to risks and uncertainties that could cause
actual results to differ materially for Affymetrix from those
projected, including, but not limited to risks of the Company's
ability to achieve and sustain higher levels of revenue, higher
gross margins, reduced operating expenses, uncertainties relating
to technological approaches, manufacturing, product development,
market acceptance (including uncertainties relating to product
development and market acceptance of the GeneChip
HighThroughputArray format), personnel retention, uncertainties
related to cost and pricing of Affymetrix products, dependence on
collaborative partners, uncertainties relating to sole source
suppliers, uncertainties relating to FDA and other regulatory
approvals, competition, risks relatingto intellectual property of
others and the uncertainties of patent protection and litigation.
These and other risk factors are discussed in Affymetrix' Form 10-K
for the year ended December 31, 2002 and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent
quarterly periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward- looking statements contained herein to reflect any change
in Affymetrix' expectations with regard thereto or any change in
events, conditions, or circumstances on which any such statements
are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are
registered trademarks owned or used by Affymetrix, Inc. DATASOURCE:
Affymetrix, Inc. CONTACT: Media Contact: Wes Conard, Associate
Director, Public Relations, +1-408-731-5791, or Investor Contact:
Doug Farrell, Vice President, Investor Relations, +1-408-731-5285,
both of Affymetrix, Inc. Web site: http://www.affymetrix.com/
Copyright
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024